Evidence map›Paper›PMID 26088929›Full record

ArticleHaematologica2015

Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.

Coline Gaillard, Taku A Tokuyasu, Galit Rosen, Jason Sotzen, Adeline Vitaliano-Prunier, Ritu Roy, Emmanuelle Passegué, Hugues de Thé, Maria E Figueroa, Scott C Kogan

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016
    Article
  15. p53 as an Effector or Inhibitor of Therapy Response.Cold Spring Harbor perspectives in medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Coline GaillardDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA Institut Universitaire d'Hématologie, Université Paris-Diderot UMR 944/7212, France.
Taku A TokuyasuComputational Biology Core, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Galit RosenCenter for Cancer and Blood Disorders, Phoenix Children's Hospital, AZ, USA.
Jason SotzenDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Adeline Vitaliano-PrunierInstitut Universitaire d'Hématologie, Université Paris-Diderot UMR 944/7212, France.
Ritu RoyComputational Biology Core, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Emmanuelle PasseguéDepartment of Medicine, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA, USA.
Hugues de ThéInstitut Universitaire d'Hématologie, Université Paris-Diderot UMR 944/7212, France.
Maria E FigueroaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Scott C KoganDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA scott.Kogan@ucsf.edu.
University of California, San Francisco · USUniversité Paris Cité · FRUniversity of Michigan–Ann Arbor · USBroad Center · USCenter for Cancer and Blood Disorders · US

Funding

Molecular Mechanisms of Leukemogenesis by PMLRAR alphaR01CA095274 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOGAN, SCOTT C. · 2002 to 2013
$2.7M
NCI NIH HHS R01 CA095274NCI NIH HHS R01-CA95274
6 · The paper itself

Abstract

Acute promyelocytic leukemia is an aggressive malignancy characterized by the accumulation of promyelocytes in the bone marrow. PML/RARA is the primary abnormality implicated in this pathology, but the mechanisms by which this chimeric fusion protein initiates disease are incompletely understood. Identifying PML/RARA targets in vivo is critical for comprehending the road to pathogenesis. Utilizing a novel sorting strategy, we isolated highly purified promyelocyte populations from normal and young preleukemic animals, carried out microarray and methylation profiling analyses, and compared the results from the two groups of animals. Surprisingly, in the absence of secondary lesions, PML/RARA had an overall limited impact on both the transcriptome and methylome. Of interest, we did identify down-regulation of secondary and tertiary granule genes as the first step engaging the myeloid maturation block. Although initially not sufficient to arrest terminal granulopoiesis in vivo, such alterations set the stage for the later, complete differentiation block seen in leukemia. Further, gene set enrichment analysis revealed that PML/RARA promyelocytes exhibit a subtle increase in expression of cell cycle genes, and we show that this leads to both increased proliferation of these cells and expansion of the promyelocyte compartment. Importantly, this proliferation signature was absent from the poorly leukemogenic p50/RARA fusion model, implying a critical role for PML in the altered cell-cycle kinetics and ability to initiate leukemia. Thus, our findings challenge the predominant model in the field and we propose that PML/RARA initiates leukemia by subtly shifting cell fate decisions within the promyelocyte compartment.

Indexed as

DNA MethylationTranscription, GeneticAnimalsAntigens, CD34Cell ProliferationCell Transformation, NeoplasticCluster AnalysisDisease Models, AnimalGene Expression ProfilingGene Expression Regulation, LeukemicGranulocyte Precursor CellsHumansImmunophenotypingLeukemia, Promyelocytic, AcuteMiceMice, TransgenicAntigens, CD34Oncogene Proteins, Fusionpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

Identifiers

PMID26088929
PMCPMC5004423
OpenAlexW2128398085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.